SMMT
Price
$15.61
Change
-$0.77 (-4.70%)
Updated
Sep 25 closing price
Capitalization
12.45B
45 days until earnings call
Intraday BUY SELL Signals
VKTX
Price
$35.56
Change
-$1.19 (-3.24%)
Updated
Sep 25 closing price
Capitalization
4.43B
31 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SMMT vs VKTX

SMMT vs VKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SMMT vs. VKTX commentary
Sep 28, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SMMT is a Hold and VKTX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
SMMT vs VKTX: Fundamental Ratings
SMMT
VKTX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
7974
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4845
P/E GROWTH RATING
1..100
6100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (53) in the Biotechnology industry is somewhat better than the same rating for SMMT (90). This means that VKTX’s stock grew somewhat faster than SMMT’s over the last 12 months.

VKTX's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as SMMT (79). This means that VKTX’s stock grew similarly to SMMT’s over the last 12 months.

VKTX's SMR Rating (98) in the Biotechnology industry is in the same range as SMMT (100). This means that VKTX’s stock grew similarly to SMMT’s over the last 12 months.

VKTX's Price Growth Rating (45) in the Biotechnology industry is in the same range as SMMT (48). This means that VKTX’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for VKTX (100). This means that SMMT’s stock grew significantly faster than VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SMMTVKTX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
86%
Bullish Trend 5 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
COMPARISON
Comparison
Sep 28, 2026
Stock price -- (SMMT: $15.61 vs. VKTX: $35.56)
Brand notoriety: SMMT and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SMMT: 59% vs. VKTX: 356%
Market capitalization -- SMMT: $12.45B vs. VKTX: $4.43B
SMMT [@Biotechnology] is valued at $12.45B. VKTX’s [@Biotechnology] market capitalization is $4.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SMMT’s FA Score shows that 1 FA rating(s) are green while VKTX’s FA Score has 0 green FA rating(s).

  • SMMT’s FA Score: 1 green, 4 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, SMMT is a better buy in the long-term than VKTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SMMT’s TA Score shows that 6 TA indicator(s) are bullish while VKTX’s TA Score has 4 bullish TA indicator(s).

  • SMMT’s TA Score: 6 bullish, 4 bearish.
  • VKTX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SMMT is a better buy in the short-term than VKTX.

Price Growth

SMMT (@Biotechnology) experienced а -12.55% price change this week, while VKTX (@Biotechnology) price change was +22.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.17%. For the same industry, the average monthly price growth was -13.24%, and the average quarterly price growth was +5.35%.

Reported Earning Dates

SMMT is expected to report earnings on Nov 11, 2026.

VKTX is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Biotechnology (-4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
SMMT
Daily Signal:
Gain/Loss:
VKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AAPU46.421.35
+3.00%
Direxion Daily AAPL Bull 2X ETF (AAPU)
USSG71.890.51
+0.71%
Xtrackers MSCI USA Selection Equity ETF (USSG)
SLYV103.990.41
+0.40%
State Street SPDR S&P 600 Small Cap Value ETF (SLYV)
RSBA19.980.03
+0.15%
Return Stacked Bonds & Merger Arbitrage ETF (RSBA)
RMRC25.45N/A
N/A
ARMOR Core Risk-Managed ETF (RMRC)